Neuro-oncology
Hemerion Therapeutics focuses on clinical research in high-grade glioma, with particular interest in glioblastoma and grade IV glioblastoma.
- Glioblastoma
- High-grade glioma
- Malignant brain tumours
The sponsor’s research activity is centered on therapies intended for patients with aggressive primary central nervous system tumours.
Photodynamic therapy
The clinical programme includes interest in intraoperative photodynamic therapy for brain tumour treatment, reflecting a therapeutic focus on light-activated approaches used during surgery.
- Intraoperative PDT
- Light-based cancer therapy
- Surgical oncology
This area links tumour-directed treatment with operative management in patients undergoing resection of glioblastoma.
Device-enabled oncology treatment
Hemerion Therapeutics also works in the interface between medical devices and oncology, with research involving a dedicated light-delivery system alongside a tumour-targeted therapeutic product.
- Therapeutic device integration
- Light delivery systems
- Oncology combination platforms
This area of interest supports treatment strategies designed for use in the operating theatre and within the broader neurosurgical setting.
Adult brain cancer care
The sponsor’s clinical work is directed toward adult patients with malignant brain cancer, including both men and women within the studied population.
- Adult oncology
- Brain tumour treatment
- Neurosurgical oncology
Its therapeutic interest lies in advancing treatment options for patients with difficult-to-treat primary brain tumours.
